Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

NEUROLOGICAL RESEARCH, published by TAYLOR & FRANCIS LTD, is a distinguished journal focusing on the diverse and evolving field of neurology. Established in 1979, this journal has been a prominent platform for disseminating groundbreaking research and clinical advances up to 2024. With an ISSN of 0161-6412 and an E-ISSN of 1743-1328, it offers valuable insights for researchers, professionals, and students interested in the intricate workings of the nervous system. The journal holds a respectable Q2 ranking in the field of Medicine (miscellaneous) and Q3 in the categories of Neurology and Clinical Neurology, reflecting its commitment to high-quality research. Although NEUROLOGICAL RESEARCH does not currently offer an open access option, its contributions to the literature are vital for fostering advancements in neurological understanding and treatment. With an engaged readership and a mission to advance scientific knowledge, NEUROLOGICAL RESEARCH serves as a crucial resource for anyone dedicated to neurological health and innovation.

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

Neurochemical Journal, published by MAIK NAUKA/INTERPERIODICA/SPRINGER, focuses on the dynamic and rapidly evolving field of neurochemistry, providing insights into cellular and molecular neuroscience. Despite the discontinuation of its coverage in Scopus, the journal remains a valuable resource for researchers and professionals seeking to explore the biochemical underpinnings of neural function and pathophysiology. With an ISSN of 1819-7124 and an E-ISSN of 1819-7132, the journal aims to publish rigorous research articles, reviews, and notes that push the boundaries of our understanding of neurochemical processes. With a ranking that places its subjects in the lower quartile of their respective fields, Neurochemical Journal offers a platform for innovative studies and discussions among up-and-coming scientists, making it a crucial outlet for advancing the discourse in this critical area of biomedical research.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Fluids and Barriers of the CNS is a premier open-access journal published by BMC, dedicated to advancing the field of neuroscience by exploring the complexities of the fluid dynamics and barriers of the central nervous system. Since its inception in 2011, the journal has established itself as a vital resource for researchers, professionals, and students alike, providing a platform for innovative research and critical discussions in areas such as cellular and molecular neuroscience, developmental neuroscience, neurology, and miscellaneous medicine. With an impressive Q1 ranking across multiple categories in 2023, and strong performance metrics such as being ranked in the 93rd percentile in Developmental Neuroscience, this journal not only highlights cutting-edge research but also contributes to the ongoing dialogue surrounding neurophysiology and pathology. As an open-access journal based in London, United Kingdom, it ensures that high-quality research is accessible to a global audience, fostering collaboration and knowledge-sharing in the neuroscientific community.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

ACTA BIOCHIMICA ET BIOPHYSICA SINICA, an esteemed journal published by SCIENCE PRESS, is a leading platform in the fields of biochemistry, biophysics, and molecular biology. Based in the United Kingdom, this journal has consistently ranked in the Q2 category for Biochemistry, Biophysics, and Medicine (miscellaneous) in 2023, showcasing its commitment to high-quality research and innovation in life sciences. With a convergence period extending from 1996 to 2024, it features critical insights into biochemical and biophysical processes that underlie biological phenomena. Researchers and professionals seeking to stay at the forefront of discoveries will find its articles to be both informative and transformative. Although not an open-access journal, ACTA BIOCHIMICA ET BIOPHYSICA SINICA aims to advance knowledge and foster collaboration among scientists worldwide, emphasizing its role in the dynamic landscape of biomedical research.

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.